Board & Management team

Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina is also a Non-Executive Director for Linear Clinical Research Limited. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT.

Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. Hugh has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has a track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.

Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, where he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that licensed the testosterone product Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.

Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Sonia has held various corporate responsibilities such as outsourcing and out-licensing, and she has promoted academic collaborations and supported R&D collaborations with external partners.

Sonia is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas.

Sonia is co-author of more than 50 scientific papers and several patents. Sonia holds a Masters degree and a PhD in industrial chemistry from Milan University (IT).

Clinton Snow has nearly 20 years experience as a technology leader with a focus in engineering management, project delivery, risk management, and assurance. Clinton is currently a non-executive director for Icetana Ltd (ASX:ICE) and provides advisory services to a family office with multiple Australian biotech investments.

Clinton holds a Bachelor of Chemical Engineering (honours) and Bachelor of Commerce degree from The University of Melbourne.

Hamish has experience in providing financial advice and CFO services to businesses ranging from small start-ups to large established businesses with turnover of over $50 million. He brings expertise in areas including financial/management reporting, Company Secretarial, cash flow management, taxation including (R&D Tax Incentive), Company Establishments, company valuations, budgeting and forecasting. Hamish is also a member of the senior management team at Bio101, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

Ash, a highly experienced clinician, has over 30 years’ experience spanning hospital clinical practice, clinical study design, medical affairs, compliance, patient safety and corporate strategy, having worked in big pharma, small biotech and clinical research organisations (CRO). Ash has prior clinical training in general and respiratory medicine, working with patients suffering from both chronic kidney and respiratory diseases. Most recently, Ash was the Medical Director for the global CRO, IQVIA, where he managed strategy, early phase clinical trial design, development and oversight for emerging biotech companies in multiple therapy areas including COVID-19. He previously held roles with AstraZeneca (Medical Director, Cardiovascular & Diabetes), Sanofi-Aventis Australia-New Zealand, Oncosil Medical and Roche.

Ash holds a Bachelor of Medicine and Surgery (MBBS) from the University of London, and an MBA and Diploma of Imperial College (DIC) from The Business School, Imperial College of Science, Technology and Medicine, London. He is also a Member of the Royal College of Physicians – London (MRCP) and has published in a number of notable medical journals.

Robert is an experienced pharmaceutical executive having lead multidisciplinary research and development teams for over 11 years. Prior to joining the Dimerix team, Robert was a Senior Development Manager at Medicines Development for Global Health, a non-profit organisation focused on efficiently developing drugs for orphan and neglected indications. In this role, he supported biotechnology and academic groups in project management roles spanning research, manufacturing, nonclinical, clinical and regulatory fields in pain, immunology, infectious diseases, and oncology. Robert has previously held roles as a Business Analyst at the Monash Vision Group, Communications Advisor at the Australian Society of Plant Scientists, and Sessional Lecturer at Monash University. Robert holds a BS in Genetics (Honours), PhD in molecular cell biology and immunology, an MBA and a graduate certificate in science commercialisation from Monash University, Australia.

Bronwyn Pollock is an experienced biotech and pharmaceutical professional with over 20 years in the industry. Prior to leading the Product Development work at Dimerix, Bronwyn was Director of Product Development at Prota Therapeutics. She has also held Senior Management positions in pharmaceutical companies including Neuren Pharmaceuticals Ltd, Hospira Australia (now Pfizer), Acrux Ltd and CSL. Her CMC (Chemistry, Manufacturing and Controls) experience comes from working in R&D, quality and program management, and she has been involved in leading teams in the development and submission of numerous dossiers to EMA, US FDA, Asia and Sth America, technology transfers and launch.